ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

GZR101-80

A development code. Also written as “GZR101 80 Injection”.

Its studies are mostly in Diabetes Mellitus, Type 2, led by Gan & Lee Pharmaceuticals.

Furthest: phase 2, since Jan 28, 20262 company-led studies, 2 open or runningNext primary completion: Feb 2, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gan & Lee Pharmaceuticals22 open or runningphase 2since Jan 28, 2026Jan 28, 2026Feb 2, 2027phase 1 · NCT07918898

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 28, 2026First study: phase 2 study in Diabetes Mellitus, Type 2First studyNCT07387003 · 345 planned · China
  2. Oct 27, 2026Phase 1 study in Healthy ParticipantsNCT07918898 · 26 planned · China

Ahead

  1. Feb 2, 2027Primary completion: phase 1 study in Healthy ParticipantsNCT07918898
  2. Feb 11, 2027Primary completion: phase 2 study in Diabetes Mellitus, Type 2NCT07387003

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07918898Healthy Participants · China1RecruitingFeb 2, 202726
NCT07387003Diabetes Mellitus, Type 2 · China2Not yet recruitingFeb 11, 2027345

How it is read

Names in the registry

  • “GZR101 80 Injection”, 1 entry
  • “GZR101-80”, 1 entry

Codes read as this program: GZR10180.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.